RecruitingPhase 2NCT05953584

A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke

Studying Sickle cell disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Forma Therapeutics, Inc.
Principal Investigator
Clinical Transparency (dept. 2834)
Novo Nordisk A/S
Intervention
Etavopivat(drug)
Enrollment
27 enrolled
Eligibility
12-16 years · All sexes
Timeline
2023 – 2027

Study locations (9)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05953584 on ClinicalTrials.gov

Other trials for Sickle cell disease

Additional recruiting or active studies for the same condition.

See all trials for Sickle cell disease →

← Back to all trials